Gilead Sciences (GILD) Income towards Parent Company (2009 - 2026)
Gilead Sciences (GILD) reported Income towards Parent Company of $2.0 billion for Q1 2026, up 53.69% on a YoY basis from $1.3 billion in Q1 2025, and down 20.06% quarter-over-quarter from $2.5 billion in Q4 2025.
Gilead Sciences (GILD) Income towards Parent Company (2009 - 2026) Analysis & Trends
Gilead Sciences has reported Income towards Parent Company for 18 years, with the latest figure at $2.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company rose 53.69% year-over-year to $2.0 billion; the trailing twelve-month figure through Mar 2026 stood at $9.6 billion (up 60.3% YoY), and the FY2025 full-year result was $8.5 billion, up 1676.62% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $2.0 billion, down from $2.5 billion in the prior quarter.
- The five-year high for Income towards Parent Company was $3.1 billion in Q3 2025, with the low at -$4.2 billion in Q1 2024.
- Historically, Income towards Parent Company has averaged $1.3 billion across 5 years, with a median of $1.6 billion in 2024.
- Annual changes were most pronounced in 2023 — Income towards Parent Company jumped 8100.0% — and 2024, when it slumped 523.88%.
- Gilead Sciences' Income towards Parent Company stood at $1.6 billion in 2022, then dropped by 13.29% to $1.4 billion in 2023, then advanced by 25.85% to $1.8 billion in 2024, then soared by 41.86% to $2.5 billion in 2025, then dropped by 20.06% to $2.0 billion in 2026.
- The last three Income towards Parent Company figures came in at $2.0 billion (Q1 2026), $2.5 billion (Q4 2025), and $3.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.02 Bn |
| Dec 31, 2025 | 2.53 Bn |
| Sep 30, 2025 | 3.05 Bn |
| Jun 30, 2025 | 1.96 Bn |
| Mar 31, 2025 | 1.32 Bn |
| Dec 31, 2024 | 1.78 Bn |
| Sep 30, 2024 | 1.25 Bn |
| Jun 30, 2024 | 1.62 Bn |
| Mar 31, 2024 | -4.17 Bn |
| Dec 31, 2023 | 1.42 Bn |
| Sep 30, 2023 | 2.17 Bn |
| Jun 30, 2023 | 1.04 Bn |
| Mar 31, 2023 | 984.00 Mn |
| Dec 31, 2022 | 1.63 Bn |
| Sep 30, 2022 | 1.79 Bn |
| Jun 30, 2022 | 1.14 Bn |
| Mar 31, 2022 | 12.00 Mn |
| Dec 31, 2021 | 376.00 Mn |
| Sep 30, 2021 | 2.59 Bn |
| Jun 30, 2021 | 1.51 Bn |